IP Library Granted Patent US 8,124,405
Granted Patent B2
US 8,124,405 · App. 11/853,517 · Granted Feb 28, 2012

Fusion proteins

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,124,405
App. No.
11/853,517
Granted
Feb 28, 2012
Kind
B2
Abstract

The invention provides a single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a target cell; a Targeting Moiety that is capable of binding to a Binding Site on the target cell, which Binding Site is capable of undergoing endocytosis to be incorporated into an endosome within the target cell; a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the Targeting Moiety; and a translocation domain that is capable of translocating the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the target cell.

Claims (13)

1. A single chain, polypeptide fusion protein having an N-terminus and a C-terminus, said fusion protein comprising:

(a) an L-chain of a botulinum neurotoxin;

(b) a PAR1 ligand located C-terminal of the L-chain;

(c) a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the L-chain and the PAR1 ligand; and

(d) a translocation domain that comprises the H N domain of a botulinum neurotoxin;

wherein the PAR1 ligand is located between the protease cleavage site and the translocation domain; and

wherein the fusion protein lacks the natural binding function of the Hc component of a clostridial neurotoxin H-chain.

2. The fusion protein according to claim 1 , wherein the fusion protein comprises a purification tag.

3. The fusion protein according to claim 2 , wherein the purification tag is joined to the fusion protein by a peptide spacer molecule.

4. The fusion protein according to claim 1 , wherein the translocation domain is separated from the PAR1 ligand by a peptide spacer molecule.

5. The fusion protein according to claim 1 , wherein the protease cleavage site is a non-clostridial protease cleavage site selected from the group consisting of: DDDDK (SEQ ID NO: 49); IEGR (SEQ ID NO: 50); IDGR (SEQ ID NO: 51); ENLYFQG (SEQ ID NO: 52); LVPRGS (SEQ ID NO: 53); and LEVLFQGP (SEQ ID NO: 54).

6. A nucleic acid sequence encoding the polypeptide fusion protein according to claim 1 .

7. A DNA vector, comprising a promoter, a nucleic acid sequence according to claim 6 located downstream of the promoter, and a terminator located downstream of said nucleic acid sequence.

Assignments (2)
CHANGE OF NAME AND ADDRESS Recorded May 15, 2017
From: SYNTAXIN LIMITED
To: IPSEN BIOINNOVATION LIMITED
Reel/Frame 042458/0982 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 9, 2007
From: FOSTER, KEITH ALAN; CHADDOCK, JOHN; MARKS, PHILIP; STANCOMBE, PATRICK; DUROSE, LYNDSEY
To: SYNTAXIN LTD.
Reel/Frame 020091/0804 →